EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY-NC 4.0

Long‐term efficacy of abrocitinib in patients with moderate‐to‐severe atopic dermatitis to 2 years

Melinda J Gooderham iD, Jonathan I Silverberg iD, Marjolein De Bruin-Weller, Leon Kircik, Diamant Thaçi, Zuotao Zhao, Fernando Valenzuela iD, Toshifumi Nomura, Andrew Selfridge, Dorothy Fan, Daniela E Myers, Pinaki Biswas und 3 weitere

Journal of the European Academy of Dermatology and Venereology · 2026-08 · 40 (8) · 1372-1381

DOI: 10.1111/jdv.70439 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 28.04.2026. Verfasst von Melinda J Gooderham und 14 weiteren Autor:innen. Beteiligte Einrichtung: SKiN Centre for Dermatology, Peterborough, Ontario, Canada. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Dermatologic Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Abrocitinib treatment previously showed clinically meaningful improvements in skin signs and symptoms in patients with moderate‐to‐severe atopic dermatitis (AD) up to 48 weeks, with a manageable safety profile.

Objective

To further evaluate long‐term efficacy and patient‐reported outcomes (PROs) with abrocitinib in patients with moderate‐to‐severe AD up to 112 weeks of treatment.

Methods

JADE EXTEND (NCT03422822), an ongoing, phase 3, long‐term extension study of previous abrocitinib trials, includes patients from qualifying trials MOA (NCT03915496), MONO‐1 (NCT03349060), MONO‐2 (NCT03575871), COMPARE (NCT03720470), TEEN (NCT03796676) and DARE (NCT04345367). Efficacy assessments include the proportion of patients achieving IGA score of 0 or 1 (IGA 0/1); absolute Eczema Area and Severity Index ≤7 (EASI ≤ 7), ≥75%/≥90%/100% improvement in EASI (EASI‐75/‐90/‐100); ≥4‐point improvement in Peak Pruritus Numerical Rating Scale (PP‐NRS4); PP‐NRS score of 0 or 1 (PP‐NRS 0/1); EASI‐90 + PP‐NRS 0/1. PROs include Dermatology Life Quality Index score of 0 or 1 (DLQI 0/1), Children's Dermatology Life Quality Index score of 0 or 1 (CDLQI 0/1), Patient Global Assessment score of 0 or 1 (PtGA 0/1), and ≥4‐point improvement in Patient‐Oriented Eczema Measure (POEM ≥ 4). Data cut‐off: 5 September 2022.

Results

At data cut‐off, 403 (42%) and 425 (56%) patients received abrocitinib 200 mg and abrocitinib 100 mg, respectively, for ≥112 weeks. Week 112 efficacy responses were IGA 0/1 57% and 52%; EASI ≤7 81% and 77%; EASI‐75 84% and 78%; EASI‐90 61% and 54%; EASI‐100 26% and 21%; PP‐NRS4 70% and 58%; PP‐NRS 0/1 43% and 33%; EASI‐90 + PP‐NRS 0/1 37% and 30%. Week 112 PROs were DLQI 0/1 43% and 41%; CDLQI 0/1 59% and 39%; PtGA 0/1 75% and 72%; POEM ≥4 88% and 81%.

Conclusions

Abrocitinib treatment resulted in clinically meaningful outcomes and improvements in PROs, including high‐threshold endpoints, in substantial proportions of patients with moderate‐to‐severe AD up to 2 years.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicDermatologic AgentsAdolescentAdultFemaleHumansMalePatient Reported Outcome MeasuresQuality of LifeSeverity of Illness IndexTreatment OutcomePyrimidinesSulfonamides

Stichwörter der Autor:innen

abrocitinibatopic dermatitisclinical trialefficacylong‐term

Substanzen

abrocitinibDermatologic AgentsPyrimidinesSulfonamides

Autor:innen und Institutionen

  • SKiN Centre for Dermatology, Peterborough, Ontario, Canada.
  • Queen's University, Kingston, Ontario, Canada.
  • Probity Medical Research, Waterloo, Ontario, Canada.
  • The George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
  • University Medical Center Utrecht, Utrecht, The Netherlands.
  • Icahn School of Medicine at Mount Sinai, New York, New York, USA.

ORCID-Profile: Melinda J Gooderham, Jonathan I Silverberg, Fernando Valenzuela, Melissa Watkins

Förderung

  • Pfizer

Zitieren

APA

Gooderham, M. J., Silverberg, J. I., De Bruin-Weller, M., Kircik, L., Thaçi, D., Zhao, Z., Valenzuela, F., Nomura, T., Selfridge, A., Fan, D., Myers, D. E., Biswas, P., Farooqui, S. A., Watkins, M., & Koppensteiner, H. (2026). Long‐term efficacy of abrocitinib in patients with moderate‐to‐severe atopic dermatitis to 2 years. Journal of the European Academy of Dermatology and Venereology, 40(8), 1372-1381. https://doi.org/10.1111/jdv.70439

Vancouver

Gooderham MJ, Silverberg JI, De Bruin-Weller M, Kircik L, Thaçi D, Zhao Z, et al. Long‐term efficacy of abrocitinib in patients with moderate‐to‐severe atopic dermatitis to 2 years. Journal of the European Academy of Dermatology and Venereology. 2026;40(8):1372-1381. doi:10.1111/jdv.70439

BibTeX
@article{Gooderham2026,
  author = {Gooderham, Melinda J and Silverberg, Jonathan I and De Bruin-Weller, Marjolein and Kircik, Leon and Thaçi, Diamant and Zhao, Zuotao and Valenzuela, Fernando and Nomura, Toshifumi and Selfridge, Andrew and Fan, Dorothy and Myers, Daniela E and Biswas, Pinaki and Farooqui, Saleem A and Watkins, Melissa and Koppensteiner, Herwig},
  title = {Long‐term efficacy of abrocitinib in patients with moderate‐to‐severe atopic dermatitis to 2 years},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2026},
  volume = {40},
  number = {8},
  pages = {1372--1381},
  doi = {10.1111/jdv.70439}
}
Kostenlos starten →